Tempus Presents Data on AI-Enabled Pre-Screening for NSCLC Biomarker Testing
OVERVIEWTempus AI has presented data demonstrating that AI-enabled pre-screening can help identify patients eligible for biomarker testing in non-small cell lung cancer (NSCLC). The research shows that AI-driven patient identification accelerates enrollment into precision medicine workflows by reducing the time clinicians spend on manual chart review and eligibility assessment. This application addresses a critical bottleneck in oncology: many patients who would benefit from targeted therapies or immunotherapies are never tested for the biomarkers that would guide treatment selection. AI pre-screening bridges this gap by flagging high-probability candidates from existing patient populations. The data supports broader trends in AI-enabled clinical trial matching and patient stratification, where machine learning models identify eligible participants faster than traditional methods. For oncology practices, this translates to improved patient outcomes and faster time-to-treatment for precision therapies. ---
Subscribe to read full wiki analysis
Full wiki content — including source provenance, contradiction tracking, related pages, and analyst notes — is available to Subscriber members.
View Plans & SubscribeNew users get a 7-day trial — no credit card required.